| 1 |
NCT00868374 |
Terminated
Has Results |
Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder |
- Major Depressive Disorder
- Generalized Anxiety Disorder
|
- Drug: Quetiapine XR
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Keming Gao
- AstraZeneca
- University Hospitals Cleveland Medical Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in 17 Item Hamilton Rating Scale for Depression (HAM-D-17)
|
23 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00868374 |
12-07-29 |
MDD/GAD |
June 2008 |
October 2011 |
October 2011 |
March 25, 2009 |
December 29, 2016 |
February 11, 2014 |
- University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
|
|
| 2 |
NCT00705003 |
Completed
Has Results |
Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Drug: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
- Drug: BCI-024 (Buspirone)
- Drug: Matching placebo
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- BrainCells Inc.
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Score on the Clinical Global Impression-Improvement (CGI-I) at Week 6
- The Change From Baseline in the CGI-S at Week 6
- The Change From Baseline in the IDS-C30 at Week 6
- (and 2 more...)
|
142 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00705003 |
CBM-IT-01 |
|
May 2008 |
December 2008 |
December 2008 |
June 25, 2008 |
June 18, 2014 |
June 18, 2014 |
- Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States - Synergy Research Centers
San Diego, California, United States - Atlanta Institute of Medicine & Research, Inc.
Altanta, Georgia, United States - (and 6 more...)
|
|
| 3 |
NCT01325532 |
Completed
Has Results |
Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Device: Active CES
- Device: Sham CES
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Fisher Wallace Labs, LLC
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in Hamilton Depression Rating Scale (HAM-D 17) Score From Baseline to Week 3
- Reported Side Effects Based on PRISE AE Scores
- Change in Global Sleep Scores on the Pittsburgh Sleep Quality Index (PSQI) From Baseline to Week 3.
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01325532 |
2010 P000461 |
|
November 2010 |
January 2014 |
January 2015 |
March 29, 2011 |
June 1, 2016 |
June 1, 2016 |
- Depression Clinical and Research Program at Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 4 |
NCT00985725 |
Completed
Has Results |
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: SPD489 (Lisdexamfetamine dimesylate)
- Drug: Matching placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF)
- Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF)
- Change From Baseline in BRIEF-A T-scores at Week 9, LOCF
- (and 12 more...)
|
143 |
All |
18 Years to 55 Years (Adult) |
NCT00985725 |
SPD489-205 |
|
October 2009 |
April 2011 |
April 2011 |
September 28, 2009 |
March 23, 2015 |
April 6, 2012 |
- Sun Valley Research Center
Imperial, California, United States - Pharmacology Research Center
Los Alamitos, California, United States - Excell Research
Oceanside, California, United States - (and 30 more...)
|
|
| 5 |
NCT01971203 |
Completed
Has Results |
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat |
- Major Depressive Disorder
- Generalized Anxiety Disorder
|
- Drug: seroquel xr
- Behavioral: CBT
|
Interventional
|
Not Applicable |
- Icahn School of Medicine at Mount Sinai
- AstraZeneca
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- MADRS
- HAM-A
- Clinical Global Impression Scales for Severity and Improvement
- Changes in Sexual Functioning Questionnaire (CSFQ)
|
62 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01971203 |
GCO 09-0807 |
|
September 2009 |
June 2013 |
June 2013 |
October 29, 2013 |
February 15, 2018 |
February 15, 2018 |
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
|
| 6 |
NCT00797901 |
Completed |
Depression Treatment in General Medical Settings |
|
- Other: Collaborative Care
|
Interventional
|
Not Applicable |
- University of Puerto Rico
- National Institute of General Medical Sciences (NIGMS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Depression
- Health-Related Functional Impairment
- Quality of Life
- (and 2 more...)
|
179 |
All |
18 Years and older (Adult, Older Adult) |
NCT00797901 |
S06GM008224 |
|
August 2004 |
April 2008 |
April 2008 |
November 25, 2008 |
August 28, 2014 |
|
- University of Puerto Rico
San Juan, Puerto Rico
|
|
| 7 |
NCT01001559 |
Completed
Has Results |
Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis |
- Major Depressive Disorder
|
- Drug: L-methylfolate
- Drug: Selective serotonin reuptake inhibitor (SSRI)
- Drug: Serotonin and norepinephrine reuptake inhibitor (SNRI)
|
Observational
|
|
- Pamlab, Inc.
- Red Oak Psychiatry Associates, PA
- Baylor Health Care System
|
Industry / Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Improvement as Measured by Change in Clinical Global Impression of Severity (CGI-S) Rating From Baseline
- Length of Time to Peak Response, as Determined by the Clinical Global Impression of Severity (CGI-S) Scale
- Number of Hospitalizations Due to MDD
- Absolute Count of Alterations in Therapy Required, Such as Dose Increases, Antidepressant Substitutions, or Addition of Augmentation Medications
|
242 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01001559 |
Pamlab D-005 |
|
August 2009 |
December 2010 |
June 2011 |
October 26, 2009 |
December 19, 2013 |
December 19, 2013 |
- Red Oak Psychiatry Associates, PA
Houston, Texas, United States
|
|
| 8 |
NCT00505518 |
Completed
Has Results |
Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home |
- Major Depressive Disorder
|
- Drug: Psychotropic medication (at discretion of psychiatrist)
- Behavioral: Collaborative psychiatric and primary medical care
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Mean Scores on Clinical Global Impressions
- Patient/Family Telepsychiatry Service Satisfaction Survey
- Nurse Telepsychiatry Services Satisfaction Questionnaire
|
9 |
All |
18 Years and older (Adult, Older Adult) |
NCT00505518 |
2006-P-001508 |
|
September 2006 |
November 2007 |
November 2007 |
July 23, 2007 |
September 17, 2013 |
September 17, 2013 |
- Depression and Clinical Research Program at Massachusetts General Hospital
Boston, Massachusetts, United States - South Cove Manor
Boston, Massachusetts, United States
|
|
| 9 |
NCT01559324 |
Completed |
Electroconvulsive Therapy (ECT) for Elderly Patients With Major Depression |
|
|
Interventional
|
Phase 4 |
- Diakonhjemmet Hospital
- MD Tor Magne Bjølseth
- MD Torfinn Lødøen Gaarden
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression
- Cognitive function
- Blood-tests
|
92 |
All |
60 Years to 85 Years (Adult, Older Adult) |
NCT01559324 |
6.2009.06 2011/02/0009 |
|
August 2009 |
July 2013 |
November 2013 |
March 21, 2012 |
July 9, 2015 |
|
- Diakonhjemmet Hospital, Department of Old Age Psychiatry
Oslo, Norway
|
|
| 10 |
NCT03329287 |
Recruiting |
Simplified Cognitive Behavioral Therapy for Generalized Anxiety Disorder and Depression |
- Generalized Anxiety Disorder
- Major Depressive Disorder
|
- Behavioral: SCBT
- Drug: SSRIs and/or SNRIs
- Behavioral: Psychological Placebo
|
Interventional
|
Not Applicable |
- Shanghai Mental Health Center
- Changhai Hospital
- Shanghai 10th People's Hospital
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- changes of The Hamilton Depression Scale (HAMD-17)
- changes of The Hamilton Anxiety Scale (HAMA-14)
- changes of The Patient Health Questionnaire (PHQ-9)
- (and 4 more...)
|
180 |
All |
18 Years to 60 Years (Adult) |
NCT03329287 |
15411950201 |
|
July 1, 2017 |
March 30, 2018 |
June 30, 2018 |
November 1, 2017 |
November 1, 2017 |
|
- Shanghai Mental Health Center
Shanghai, Shanghai, China
|
|
| 11 |
NCT02004145 |
Completed |
Trial of a Positive Psychology Intervention in Major Depressive Disorder |
- Major Depressive Disorder
|
- Behavioral: Positive Psychology
- Behavioral: Control Condition
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- American Foundation for Suicide Prevention
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in BHS Scores
- Change in CHRT Scores
- Change in QIDS-SR Scores
|
65 |
All |
18 Years and older (Adult, Older Adult) |
NCT02004145 |
2013P001234
SRG-2-019-12 |
HOPE |
October 2013 |
September 2015 |
September 2015 |
December 6, 2013 |
April 19, 2016 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 12 |
NCT01667926 |
Completed
Has Results |
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Ketamine
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale - Suicidal Ideation (HDRS-SI)
- HDRS-28 Total
|
37 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01667926 |
2012-P-001042 |
|
January 2013 |
October 2015 |
November 2015 |
August 17, 2012 |
April 20, 2017 |
April 20, 2017 |
- Depression Clinical and Reseach Program - MGH
Boston, Massachusetts, United States
|
|
| 13 |
NCT00683852 |
Completed
Has Results |
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy |
- Major Depressive Disorder
|
- Drug: Aripiprazole 5mg
- Drug: Aripiprazole 2mg
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
- Bristol-Myers Squibb
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate
- MADRS (Montgomery-Asberg Depression Rating Scale) Readmission Rate
- Mean Change in MADRS (Montgomery-Asberg Depression Rating Scale) Score From Baseline to the End of Follow-up
- (and 2 more...)
|
225 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00683852 |
BMS - 2008A053242 |
|
September 2008 |
September 2009 |
September 2009 |
May 26, 2008 |
July 19, 2017 |
July 19, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 14 |
NCT01103271 |
Completed
Has Results |
Pilot Study of Open-label Placebo to Treat Major Depressive Disorder |
- Major Depressive Disorder
|
- Other: Open-label Placebo
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- Harvard University
- National Center for Complementary and Integrative Health (NCCIH)
- Massachusetts General Hospital
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Feasibility
- Pre-Post Efficacy
|
20 |
All |
18 Years to 60 Years (Adult) |
NCT01103271 |
2009p002469
K24AT004095 |
|
May 2010 |
May 2011 |
May 2011 |
April 14, 2010 |
January 14, 2013 |
January 14, 2013 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 15 |
NCT01787240 |
Terminated
Has Results |
Neurobiological Bases of Placebo Response in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Escitalopram 10mg
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Feasibility
- Effects of Acute Tryptophan Depletion on Mood
|
20 |
All |
18 Years to 60 Years (Adult) |
NCT01787240 |
2012P001241 |
|
November 2012 |
August 2016 |
August 2016 |
February 8, 2013 |
May 16, 2017 |
April 14, 2017 |
- Massachusetts General Hospital Depression Clinical and Research Program
Boston, Massachusetts, United States
|
|
| 16 |
NCT02890212 |
Recruiting |
Selenium as Augmentation Treatment for Sertraline Resistant Major Depression |
|
- Dietary Supplement: selenium supplementation
- Dietary Supplement: placebo
|
Interventional
|
Not Applicable |
- University of Sao Paulo General Hospital
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depressive Rating Scale
- Montgomery-Asberg Depression Rating Scale
- Clinical Global Impression Scale
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02890212 |
Selen-2015 |
|
August 2005 |
December 2018 |
December 2018 |
September 7, 2016 |
May 4, 2018 |
|
- Instituto de Psiquiatria - Hcfmusp
São Paulo, Brazil
|
|
| 17 |
NCT01613820 |
Withdrawn |
Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Ketamine
- Drug: Scopolamine
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale - 28 items
- Systematic Assessment for Treatment Emergent Events (SAFTEE)
|
0 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01613820 |
2012-P-000624 |
|
September 2015 |
February 2017 |
February 2017 |
June 7, 2012 |
February 19, 2018 |
|
- Depression Clinical and Reseach Program - MGH
Boston, Massachusetts, United States
|
|
| 18 |
NCT00361374 |
Completed
Has Results |
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression |
- Major Depressive Disorder
|
- Dietary Supplement: eicosapentaenoic acid
- Dietary Supplement: docosahexaenoic acid
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
- Cedars-Sinai Medical Center
- National Institute of Mental Health (NIMH)
- Massachusetts General Hospital
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Score on a Depression Severity Rating Scale Over Eight Weeks
|
196 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00361374 |
2005P002337
5R01MH074085 |
|
July 2006 |
February 2013 |
March 2013 |
August 8, 2006 |
July 18, 2014 |
July 18, 2014 |
- Depression Clinical Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 19 |
NCT01337609 |
Terminated
Has Results |
Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder |
- Major Depressive Disorder
- Irritable Bowel Syndrome
|
- Drug: Ganeden BC30
- Other: Placebo (sugar pill)
- Other: Ganeden BC30, Placebo (sugar pill)
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Ganeden Biotech, Inc.
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
- IBS Severity Scoring System (IBS-SSS)
- Visual Analog Scale (VAS)
- (and 2 more...)
|
5 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01337609 |
2008P002387 |
|
June 2011 |
February 2012 |
February 2012 |
April 19, 2011 |
August 9, 2013 |
August 9, 2013 |
- Burlington Medical Associates
Burlington, Massachusetts, United States - Charles River Medical Associates
Westborough, Massachusetts, United States
|
|
| 20 |
NCT00831415 |
Completed
Has Results |
Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Drug: desvenlafaxine succinate sustained release tablets
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score
- Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
- Number of Participants With Categorical Scores on Clinical Global Impression-Improvement (CGI-I)
- Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score
|
304 |
All |
20 Years and older (Adult, Older Adult) |
NCT00831415 |
3151A1-3350
B2061002 |
|
March 2009 |
March 2011 |
March 2011 |
January 29, 2009 |
January 30, 2012 |
January 30, 2012 |
- Pfizer Investigational Site
Aichi, Japan - Pfizer Investigational Site
Chiba, Japan - Pfizer Investigational Site
Fukuoka, Japan - (and 14 more...)
|
|
| 21 |
NCT00464711 |
Completed
Has Results |
Brain GABA Levels and Treatment Response in Major Depressive Disorder |
- Major Depressive Disorder
|
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Mclean Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response and Remitter Status at Endpoint, Based on Change in Depression Severity Rating Scores
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00464711 |
2006-P-001295 |
|
September 2006 |
September 2009 |
September 2009 |
April 24, 2007 |
January 4, 2017 |
January 4, 2017 |
- Depression Clinical and Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 22 |
NCT00633399 |
Completed
Has Results |
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs |
- Major Depressive Disorder
|
- Drug: Ziprasidone
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- University of Alabama at Birmingham
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2
- Remission Rates (HAM-D 17 Scores of Less Than 8) After Treatment Phase 2.
- Comparing Scores on HAM-D 17 Baseline Visit to Phase 2 Final Visit at Week 8
|
458 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00633399 |
2007-P-002361 |
|
July 2008 |
March 2014 |
March 2014 |
March 12, 2008 |
July 3, 2014 |
July 3, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Massachusetts General Hospital- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
|
| 23 |
NCT00705185 |
Completed |
Exploring a Potential Blood Test to Diagnose Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational
|
|
- Massachusetts General Hospital
- Precision Human Biolaboratories
- Cambridge Health Alliance
- (and 4 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- 16 Biological Markers; Group comparison between adults with Major Depressive Disorder and healthy controls
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00705185 |
2007-P-002525 |
Bio-TestMDD |
April 2008 |
June 2010 |
June 2010 |
June 25, 2008 |
June 8, 2010 |
|
- University of Connecticut Health Center
Farmington, Connecticut, United States - Psychiatric Medicine Associates, L.L.C.
Chicago, Illinois, United States - Massachusetts General Hosptial
Boston, Massachusetts, United States - (and 2 more...)
|
|
| 24 |
NCT01244711 |
Terminated
Has Results |
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines |
- Major Depression
- Generalized Anxiety Disorder
|
|
Interventional
|
Phase 4 |
- Weill Medical College of Cornell University
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery Asberg Depression Rating Scale (MADRS)
|
1 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01244711 |
IRUSQUET0483 |
|
September 2008 |
September 2011 |
September 2011 |
November 19, 2010 |
April 3, 2015 |
March 6, 2015 |
- Weill Cornell Medical College
New York, New York, United States
|
|
| 25 |
NCT00880399 |
Terminated
Has Results |
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: orvepitant
- Other: placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the 17-item Hamilton Depression Rating Scale (HAM-D) Total Score
- Percentage of Participants With a >= 50 Percent (%) Reduction From Baseline in HAM-D Total Score
- Number of Participants With (Maintained) Clinical Response
- (and 14 more...)
|
328 |
All |
18 Years to 64 Years (Adult) |
NCT00880399 |
111733 |
orvepitant MDD |
March 1, 2009 |
June 1, 2010 |
June 16, 2010 |
April 13, 2009 |
September 12, 2017 |
September 12, 2017 |
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Scottsdale, Arizona, United States - GSK Investigational Site
Arcadia, California, United States - (and 17 more...)
|
|
| 26 |
NCT00107120 |
Completed
Has Results |
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Escitalopram
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score
- Clinical Global Impressions - Improvement
|
312 |
All |
12 Years to 17 Years (Child) |
NCT00107120 |
SCT-MD-32 |
|
March 2005 |
May 2007 |
|
April 6, 2005 |
April 6, 2012 |
November 4, 2009 |
- University of California at Davis, MIND Institute, Health Services
Sacramento, California, United States - UCSD Outpatient Psychiatry Services
San Diego, California, United States - PCSD - Feighner Research
San Diego, California, United States - (and 25 more...)
|
|
| 27 |
NCT00300378 |
Completed |
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: desvenlafaxine 50 mg
- Drug: desvenlafaxine 100 mg
|
Interventional
|
Phase 3 |
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary efficacy variable will be the change from baseline on the 17-item of the Hamilton Depression rating scale (HAM-D17 score) at the final on therapy evaluation
- The Global Clinical Improvement will be the key secondary efficacy variable.
|
480 |
All |
18 Years and older (Adult, Older Adult) |
NCT00300378 |
3151A1-333 |
|
March 2006 |
|
January 2007 |
March 8, 2006 |
December 5, 2007 |
|
- Rijeka, Croatia
- Split, Croatia
- Zagreb, Croatia
- (and 40 more...)
|
|
| 28 |
NCT00844974 |
Completed |
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms |
- Major Depression
- Bipolar Disorder
|
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- To examine the relationship between severity and type of depression with cognitive deficits
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT00844974 |
2007-p-001665 |
|
December 2007 |
December 2012 |
December 2012 |
February 16, 2009 |
November 18, 2013 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 29 |
NCT02058693 |
Completed |
Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT) |
- Major Depressive Disorder
|
- Drug: mixed salts amphetamine
|
Interventional
|
Phase 4 |
- Rush University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in scores on the Massachusetts General Hospital Cognitive and Physical Functioning Questionaire
- Change in scores on the Montgomery Asberg Depression Rating Scale
- Change in scores on the Quick Inventory of Depressive Symptomatology Self Report 16
|
45 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02058693 |
CTHF-1 |
|
December 2010 |
December 2014 |
December 2014 |
February 10, 2014 |
December 19, 2014 |
|
- Rush University Medical Center
Chicago, Illinois, United States
|
|
| 30 |
NCT00321152 |
Completed |
A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Other: 6(S)-5-MTHF (a Medical Food)
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Pamlab, L.L.C.
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
150 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00321152 |
2006P000604 |
|
November 2006 |
August 2008 |
June 2010 |
May 3, 2006 |
June 8, 2010 |
|
- University of California San Diego School of Medicine
San Diego, California, United States - Rush University Medical Center, Psychiatric Medicine Associates, LLC
Chicago, Illinois, United States - Lousiana State University Health Sciences Center
New Orleans, Louisiana, United States - (and 8 more...)
|
|
| 31 |
NCT01579942 |
Terminated |
Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression |
- Major Depressive Disorder
|
|
Observational
|
|
- Massachusetts General Hospital
- ElMindA Ltd
- Massachusetts General Hospital
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Brain Network Analysis group patterns
- Identify possible predictors of treatment response
|
70 |
All |
18 Years to 55 Years (Adult) |
NCT01579942 |
2011P000200 |
|
April 2012 |
|
|
April 18, 2012 |
March 6, 2017 |
|
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
|
| 32 |
NCT00892463 |
Completed |
Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: Quetiapine (Seroquel) XR
|
Interventional
|
Phase 4 |
- Sunnybrook Health Sciences Centre
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The QIDS-SR16 (Quick Inventory of Depressive Symptomatology - Self-report)
- HADS (Hamilton Anxiety Depression Scale) VADIS
|
26 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00892463 |
D1443L00072 |
|
May 2009 |
December 2010 |
December 2010 |
May 4, 2009 |
July 28, 2011 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
|
| 33 |
NCT01318434 |
Completed |
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) |
- Major Depressive Disorder
|
- Drug: EB-1010 25mg BID
- Drug: SSRI Active
- Drug: EB-1010 50mg BID
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Euthymics BioScience, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in MADRS Score
- Change in Clinical Global Severity Scale
|
342 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01318434 |
EB-1010-301 |
|
February 2011 |
February 2013 |
February 2013 |
March 18, 2011 |
December 4, 2015 |
|
- Pacific Clinical Research Medical Group
Arcadia, California, United States - Southwest Research, Inc.
Beverly Hills, California, United States - Synergy Clinical Research Center
National City, California, United States - (and 40 more...)
|
|
| 34 |
NCT02048423 |
Unknown † |
An Open Prospective Trial of IV Ketamine in Suicidal Adolescents |
- Major Depressive Disorder
|
|
Interventional
|
Phase 2
Phase 3 |
- Nationwide Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Quick Inventory of Depression Clinician (QIDS-C) total scores from baseline to endpoint and Clinical Global Improvement Score.
- Clinical Global Assessment Scale
|
10 |
All |
12 Years to 17 Years (Child) |
NCT02048423 |
IRB12-00445 |
|
June 2013 |
June 2015 |
June 2015 |
January 29, 2014 |
January 29, 2014 |
|
- Nationwide Children's Hospital
Columbus, Ohio, United States
|
|
| 35 |
NCT01309542 |
Completed |
Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Desvenlafaxine Succinate
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number (%) of Subjects Reporting Adverse Events during Treatment
- Number (%) of Subjects With Changes in Vital Signs (Blood Pressure, Pulse Rate, Weight) of Potential Clinical Importance
- Number (%) of Subjects With Laboratory Test Results (Hematology, Blood Chemistry, Lipid Profile, Urinalysis) of Potential Clinical Importance
- (and 4 more...)
|
1403 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01309542 |
3151A1-303
B2061069 |
|
August 2003 |
March 2006 |
March 2006 |
March 7, 2011 |
April 26, 2011 |
|
- Birmingham Research Group Inc.
Birmingham, Alabama, United States - Pivotal Research Centers 13128 North 94th Drive, Suite 200
Mesa, Arizona, United States - Pivotal Research
Peoria, Arizona, United States - (and 114 more...)
|
|
| 36 |
NCT00711737 |
Completed |
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months |
- Major Depression
- Generalized Anxiety Disorder
- Panic Disorder
|
|
Observational
|
|
- Changi General Hospital
- Changi General Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
27 |
All |
21 Years and older (Adult, Older Adult) |
NCT00711737 |
2008.06 |
|
September 2008 |
October 2010 |
October 2010 |
July 9, 2008 |
June 17, 2011 |
|
- Changi General Hospital
Singapore, Singapore
|
|
| 37 |
NCT01310140 |
Terminated |
Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features |
- Major Depressive Disorder
- Major Depressive Disorder w/ Psychotic Features
- Metabolic Syndrome
|
|
Observational
|
|
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Massachusetts General Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The primary measure is any change in fasting insulin from admission to discharge while subjects are inpatient.
- The first secondary measure is a fasting lipid panel, including fasting total cholesterol, fasting LDL, fasting HDL, and fasting triglycerides; we want to measure a change in data from admission to discharge
- Fasting glucose will be a separate secondary outcome measure; we want to measure a change in data from admission to discharge
- (and 6 more...)
|
14 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01310140 |
2009-P-002723 |
|
January 2011 |
September 2012 |
September 2012 |
March 8, 2011 |
February 13, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 38 |
NCT03222752 |
Recruiting |
Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder |
- Major Depressive Disorder
|
- Device: Cranial Electrotherapy Stimulation
- Device: Sham Cranial Electrotherapy Stimulation
|
Interventional
|
Not Applicable |
- Electromedical Products International, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Depression Scale
- Clinical Global Impression - Severity of Illness
- Clinical Global Impression - Global Improvement
|
141 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03222752 |
MDD1 |
|
June 5, 2017 |
June 2018 |
June 2018 |
July 19, 2017 |
August 1, 2017 |
|
- Electromedical Products
Mineral Wells, Texas, United States
|
|
| 39 |
NCT01260649 |
Terminated
Has Results |
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression |
- Major Depressive Disorder
|
- Drug: ketamine
- Other: IV Saline
- Procedure: ECT
- (and 2 more...)
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Hamilton Depression Rating Scale - 28
- Number of Participants With Cognitive Side Effects
|
17 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01260649 |
2010P001672 |
|
November 1, 2010 |
October 26, 2012 |
November 1, 2012 |
December 15, 2010 |
May 22, 2017 |
April 14, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 40 |
NCT01254305 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Paroxetine, Sertraline, Citalopram or Fluoxetine.
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
- Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
- Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
|
262 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01254305 |
LVM-MD-06 |
|
April 2011 |
July 2012 |
July 2012 |
December 6, 2010 |
August 6, 2014 |
August 6, 2014 |
- Forest Investigative Site 010
Birmingham, Alabama, United States - Forest Investigative Site 002
Little Rock, Arkansas, United States - Forest Investigative Site 001
Cerritos, California, United States - (and 17 more...)
|
|
| 41 |
NCT02553915 |
Active, not recruiting |
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach |
- Major Depressive Disorder
- Overweight
- Inflammation
|
- Other: Placebo
- Drug: EPA 1 g/day
- Drug: EPA 2 g/day
- Drug: EPA 4 g/day
|
Interventional
|
Phase 2
Phase 3 |
- Massachusetts General Hospital
- Emory University
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change in plasma concentration of inflammatory biomarkers
- Mean change in depression severity score
- Mean change in plasma concentration of mitogen-stimulated PBMC IL-6
- (and 2 more...)
|
100 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02553915 |
R01AT008857-01 |
|
December 2015 |
July 13, 2018 |
October 13, 2018 |
September 18, 2015 |
August 21, 2018 |
|
- Emory University School of Medicine
Atlanta, Georgia, United States - Depression Clinical and Research Program at Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 42 |
NCT02165449 |
Recruiting |
Biomarkers of Fast Acting Therapies in Major Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 1 |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Hamilton Depression Rating Scale measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- Change in the Hamilton Depression Rating Scale measured between the last ketamine infusion treatment and 5 week follow-up
- Change in gene expression measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- (and 7 more...)
|
60 |
All |
18 Years to 64 Years (Adult) |
NCT02165449 |
HS001796
K24MH102743
U01MH110008 |
|
June 2014 |
August 2020 |
August 2021 |
June 17, 2014 |
August 28, 2018 |
|
- Geffen School of Medicine, UCLA
Los Angeles, California, United States
|
|
| 43 |
NCT00731653 |
Completed
Has Results |
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Drug: Combination Product: BCI-024 + BCI-049
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- BrainCells Inc.
- Massachusetts General Hospital
|
Other / Industry |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Primary Safety and Tolerability Outcome Measure is Reported Adverse Events.
|
81 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00731653 |
CBM-IT-01-EXT |
|
July 2008 |
December 2008 |
January 2009 |
August 11, 2008 |
December 17, 2013 |
December 17, 2013 |
- Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States - Synergy Research Centers
San Diego, California, United States - Atlanta Institute of Medicine & Research, Inc.
Altanta, Georgia, United States - (and 6 more...)
|
|
| 44 |
NCT00961454 |
Completed |
Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression |
- Major Depression
- Anxiety Disorder
- Post-Traumatic Stress Disorder
- Substance Abuse Disorder
|
- Device: Photobiomodulation with a super-luminous light emitting diode
|
Interventional
|
Phase 1 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale
- Hamilton Anxiety Rating Scale
|
10 |
All |
18 Years to 60 Years (Adult) |
NCT00961454 |
2008P-000937 |
|
January 2009 |
June 2009 |
June 2009 |
August 19, 2009 |
August 19, 2009 |
|
- Wellman Center for Photomedicine, Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 45 |
NCT00955474 |
Terminated
Has Results |
Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms |
- Major Depressive Disorder With Psychotic Features
|
- Drug: Quetiapine
- Drug: escitalopram
- Drug: Sertraline
- Drug: Citalopram
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression
- Psychosis
- Fasting Blood Glucose
- (and 12 more...)
|
32 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT00955474 |
2008P001022 |
Seroquel |
September 2008 |
January 2013 |
January 2013 |
August 10, 2009 |
April 20, 2017 |
March 28, 2016 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 46 |
NCT02473783 |
Completed
Has Results |
The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD |
- Major Depressive Disorder
|
- Drug: Sertraline HCl
- Other: I-123-ADAM SPECT
|
Interventional
|
Phase 2 |
- Tri-Service General Hospital
- Institute of Nuclear Energy Research, Taiwan
- Tri-Service General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The SERT Binding Potential (BP) --(Only the Treatment Group Was Assessed)
- Hamilton Depression Rating Scale (HAM-D) Total Scores
- Safety Assessments - the Tolerability of Injection of I-123-ADAM Solution
|
37 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT02473783 |
INEI-1A20090409 |
STAPMDDTDM |
October 2011 |
November 2012 |
November 2012 |
June 17, 2015 |
January 19, 2018 |
December 21, 2017 |
|
|
| 47 |
NCT00824044 |
Completed
Has Results |
Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression |
- Major Depressive Disorder
|
- Behavioral: Cognitive Behavioral Therapy (CBT)
- Drug: Escitalopram
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Hamilton Depression Rating Scale (HAM-D-17) Scores
- Change in Absolute Beta Power in Channel 4
- Change in Absolute Theta Power From Channel 1
- (and 7 more...)
|
39 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00824044 |
2008-P-000838 |
|
July 2008 |
March 2011 |
March 2011 |
January 16, 2009 |
January 5, 2018 |
January 8, 2013 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 48 |
NCT01147913 |
Completed |
Computerized Information-Processing Bias Retraining in Depressed Adolescents |
|
- Behavioral: Computerized Information-Processing Bias Retraining
- Behavioral: Attention Control Training
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Test of Interpretation Bias (TIB)
- Test of Interpretation Bias
- Kiddie-Schedule of Affective Disorders and Schizophrenia-Epidemiologic Version (K-SADS-E; Orvaschek & Puig-Antich, 1987)
- (and 5 more...)
|
48 |
All |
14 Years to 21 Years (Child, Adult) |
NCT01147913 |
F32MH088065-01 |
|
March 2010 |
April 2012 |
April 2012 |
June 22, 2010 |
May 3, 2012 |
|
- Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital
Cambridge, Massachusetts, United States
|
|
| 49 |
NCT01573741 |
Unknown † |
Study of Ketamine as an Antidepressant in Major Depressive Disorder |
- Major Depressive Disorder
|
|
Interventional
|
Phase 1
Phase 2 |
- Shi Jinyun
- Jinling Hospital, China
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
35 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01573741 |
nju-030614 |
|
February 2012 |
December 2012 |
February 2013 |
April 9, 2012 |
May 4, 2012 |
|
- The PLA 102nd Hospital and mental health center of military
Changzhou, Jiangsu, China
|
|
| 50 |
NCT00361218 |
Completed
Has Results |
Biological Markers of Response to Treatment in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: open-label selective serotonin reuptake inhibitor (SSRI)
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum Brain-derived Neurotrophic Factor (BDNF) Levels
- Quantitative Electroencephalogram (QEEG) Parameters as Predictors of Response
|
72 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00361218 |
2005P000413 |
|
October 2005 |
December 2008 |
December 2008 |
August 8, 2006 |
May 11, 2018 |
September 26, 2013 |
|
|
| 51 |
NCT01851967 |
Completed |
Effectiveness and Acceptability of MoodGYM in Treating Depressive Symptoms in Chinese Americans |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Center for Epidemiologic Studies Depression Scale (CES-D)
|
112 |
All |
18 Years and older (Adult, Older Adult) |
NCT01851967 |
2012-P-002340 |
|
September 2014 |
December 2015 |
November 2016 |
May 13, 2013 |
December 1, 2016 |
|
- Massachusetts General Hospital Depression Clinical and Research Program
Boston, Massachusetts, United States - Ying Wang
Beijing, China
|
|
| 52 |
NCT01438242 |
Withdrawn |
An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Efficacy
- Medication Adherence
- Resource Utilization
- (and 2 more...)
|
0 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01438242 |
AT1 |
|
January 2015 |
January 2016 |
January 2016 |
September 22, 2011 |
March 23, 2015 |
|
- Genomind, LLC
Chalfont, Pennsylvania, United States
|
|
| 53 |
NCT01326793 |
Completed |
Internet-Based Depression Screening for College Students |
- Major Depressive Disorder
|
- Other: Skype Consultation
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- 9-item Patient Health Questionnaire
|
1900 |
All |
18 Years and older (Adult, Older Adult) |
NCT01326793 |
2008P001438 |
|
September 2008 |
December 2014 |
December 2014 |
March 31, 2011 |
April 28, 2015 |
|
- Depression Clinical and Research Program at Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 54 |
NCT03057691 |
Recruiting |
The Impact of Depression and/or Anxiety on PCI Patients |
- Acute Coronary Syndrome
- MAjor Depressive Disorder
- Generalized Anxiety Disorder
|
- Other: antidepressive and anti-anxiety therapy
|
Observational
|
|
- First Affiliated Hospital Xi'an Jiaotong University
- Shaanxi Provincial People's Hospital
- Xi An No.1 Hospital
- (and 8 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Major Adverse Cardiovascular Events
- all-cause mortality
- heart failure
- (and 6 more...)
|
5000 |
All |
24 Years and older (Adult, Older Adult) |
NCT03057691 |
XJTU1AF-CRF-2016-004 |
|
March 11, 2017 |
December 2019 |
January 2020 |
February 20, 2017 |
March 2, 2018 |
|
- First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
|
| 55 |
NCT01464229 |
Completed
Has Results |
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability |
- Major Depressive Disorder
|
- Drug: Iloperidone
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Maurizio Fava, MD
- Novartis Pharmaceuticals
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01464229 |
2011P002043 |
|
April 2012 |
December 2014 |
December 2014 |
November 3, 2011 |
April 11, 2017 |
April 11, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 56 |
NCT01473381 |
Completed
Has Results |
Safety and Efficacy of Vilazodone in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Vilazodone
- Drug: Placebo to citalopram
- Drug: Placebo to vilazodone
- Drug: Citalopram
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 10
- Change From Baseline to Week 10 in the Clinical Global Impressions-Severity (CGI-S) Scale Score
- Percentage of Participants With a Montgomery-Åsberg Depression Rating Scale (MADRS) Sustained Response
|
1162 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01473381 |
VLZ-MD-01 |
VLZ-MD-01 |
December 2011 |
June 2013 |
June 2013 |
November 17, 2011 |
August 8, 2014 |
August 8, 2014 |
- Forest Investigative Site 036
Birmingham, Alabama, United States - Forest Investigative Site 016
Dothan, Alabama, United States - Forest Investigative Site 033
Scottsdale, Arizona, United States - (and 51 more...)
|
|
| 57 |
NCT02715778 |
Enrolling by invitation |
Translational Investigation of Gestational Environment on Neurobehavioral Function in Children |
- Major Depressive Disorder
|
|
Observational
|
|
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Observational Model: Family-Based
- Time Perspective: Cross-Sectional
|
- neuropsychological functioning as assessed by CANTAB research battery
|
100 |
All |
6 Years and older (Child, Adult, Older Adult) |
NCT02715778 |
2015P001326 |
|
February 2016 |
September 2017 |
June 2019 |
March 22, 2016 |
August 20, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Boston Children's Hospital
Boston, Massachusetts, United States
|
|
| 58 |
NCT00157547 |
Completed |
Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression |
- Major Depressive Disorder
|
- Drug: Selective serotonin reuptake inhibitors (SSRI)
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Medtronic - MITG
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
95 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00157547 |
2002-P-001784 |
|
April 2003 |
August 2006 |
August 2006 |
September 12, 2005 |
May 28, 2008 |
|
|
|
| 59 |
NCT02253225 |
Recruiting |
Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study |
- Bipolar Disorder
- Major Depression
- Rumination
|
- Other: Functional Magnetic Resonance Imaging (fMRI)
|
Observational
|
|
- Massachusetts General Hospital
- Brain & Behavior Research Foundation
- Massachusetts General Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Functional Magnetic Resonance Imaging (fMRI) to examine self processing and self focus
|
60 |
All |
18 Years to 64 Years (Adult) |
NCT02253225 |
2012P000714
19531 |
|
January 2013 |
August 2018 |
January 2019 |
October 1, 2014 |
August 29, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 60 |
NCT02900092 |
Completed |
Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression (MADRS) Scale
|
10 |
Female |
50 Years to 75 Years (Adult, Older Adult) |
NCT02900092 |
2016P001182 |
|
November 2016 |
January 12, 2018 |
January 12, 2018 |
September 14, 2016 |
September 14, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 61 |
NCT03460574 |
Completed |
Targeting Cognitive Immunization in Depression |
- Major Depressive Disorder
|
- Behavioral: INFORMATION
- Behavioral: SALIENCE
- Behavioral: ATTENTION
- Behavioral: CONTROL
|
Interventional
|
Not Applicable |
- Philipps University Marburg Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Performance Expectations Scale - generalized
- Performance Expectations Scale - task-specific
|
135 |
All |
18 Years and older (Adult, Older Adult) |
NCT03460574 |
2017-39k |
|
October 14, 2017 |
April 30, 2018 |
August 21, 2018 |
March 9, 2018 |
August 23, 2018 |
|
- Schoen Klinik Bad Arolsen
Bad Arolsen, Hessen, Germany
|
|
| 62 |
NCT01538199 |
Completed
Has Results |
Transcranial Laser Therapy for Major Depressive Disorder |
- Major Depressive Disorder
|
- Device: Near-infrared radiation via Transcranial LED Therapy
- Device: Sham device
|
Interventional
|
Not Applicable |
- Paolo Cassano
- Mclean Hospital
- North Suffolk Mental Health Association
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Hamilton Depression Rating Scale (HAM-D 17) Score
- Systematic Assessment for Treatment Emergent Events-systematic Inquiry (SAFTEE-SI)
- Number of Participants With Adverse Events
|
28 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01538199 |
2010P002718
2010A050442 |
ELATED |
February 2012 |
August 2015 |
August 2015 |
February 24, 2012 |
November 29, 2017 |
November 29, 2017 |
- Massachusetts General Hospital- Depression Clinical and Research Program
Boston, Massachusetts, United States - Chelsea Counseling Center- North Suffolk Mental Health Association
Chelsea, Massachusetts, United States
|
|
| 63 |
NCT00452543 |
Completed
Has Results |
Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism |
- Major Depressive Disorder
- Alcohol Abuse
- Alcohol Dependence
|
- Drug: acamprosate
- Drug: escitalopram
- Behavioral: Medical management
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Mean Score on the Hamilton Rating Scale for Depression -- 17 Items (HAM-D-17)
- Total Drinking Days on the Alcohol Timeline Followback (TLFB)
- Total Drinks Consumed Per Week on the TLFB
- Total Drinks Consumed Per Drinking Day on the TLFB
|
23 |
All |
18 Years to 64 Years (Adult) |
NCT00452543 |
2006-P-001592/1 |
|
March 2007 |
May 2010 |
May 2010 |
March 27, 2007 |
July 9, 2012 |
July 9, 2012 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 64 |
NCT02422303 |
Terminated
Has Results |
Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms |
- Depression
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
- The University of Texas Health Science Center at San Antonio
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Depression Score Using Goldberg Depression Screening Test
|
12 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT02422303 |
HSC20150248H |
|
December 2015 |
September 2016 |
September 2016 |
April 21, 2015 |
February 15, 2018 |
February 15, 2018 |
- University Hospital
San Antonio, Texas, United States
|
|
| 65 |
NCT02959307 |
Recruiting |
Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3) |
- Depression
- Major Depressive Disorder
|
- Device: Transcranial Light Therapy
- Device: Sham Transcranial Light Therapy
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- LiteCure LLC
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Quick Inventory of Depressive Symptomatology
- Pattern Separation Task
- Multi-Source Interference Task
- Hamilton Depression Rating Scale - 17 items
|
50 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02959307 |
2016P001490 |
ELATED-3 |
November 2016 |
November 2018 |
November 2018 |
November 9, 2016 |
July 18, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Nathan S. Kline Institute for Psychiatric Research
Orangeburg, New York, United States
|
|
| 66 |
NCT01263730 |
Completed |
Tai Chi Training for Treating Depressed Chinese Americans |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Centers for Disease Control and Prevention
- Massachusetts General Hospital
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Depressive Symptoms
- Psychological questionnaires, specifically the Quality of Life Enjoyment questionnaire.
|
38 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01263730 |
2008P000262 |
|
February 2008 |
August 2010 |
August 2010 |
December 21, 2010 |
April 19, 2012 |
|
- South Cove
Boston, Massachusetts, United States
|
|
| 67 |
NCT00555997 |
Completed
Has Results |
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Ziprasidone
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- Cambridge Health Alliance
- University of Connecticut
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HAM-D-17) Scores
- Responder/Non-responder
- Change in 6-VAS-D Scores During Each Phase.
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00555997 |
2007-P-000623 |
Geodon |
March 2008 |
June 2010 |
June 2010 |
November 9, 2007 |
July 3, 2014 |
July 3, 2014 |
- Cedars-Sinai Medical Center
Los Angeles, California, United States - University of Connecticut Health Center
Farmington, Connecticut, United States - Comprehensive Psychiatric Care
Norwich, Connecticut, United States - (and 4 more...)
|
|
| 68 |
NCT03084042 |
Recruiting |
Emotional Brain Networks & Cognitive Functioning in Depression and Anxiety |
- Major Depressive Disorder
- General Anxiety Disorder
|
|
Observational
|
|
- University of Electronic Science and Technology of China
- Sichuan Provincial People's Hospital
- The Fourth People's Hospital of Chengdu
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Brain activity in the emotional and cognitive core regions of the brain as assessed by fMRI
- Behavioral performance during the fMRI: face processing
- Behavioral performance during the fMRI: empathy reactivity
- (and 4 more...)
|
105 |
All |
18 Years to 55 Years (Adult) |
NCT03084042 |
UESTC-neuSCAN-23 |
|
July 2016 |
December 2018 |
June 2019 |
March 20, 2017 |
March 20, 2017 |
|
- School of Life Science and Technology, University of Electronic Science and Technology of China
Chendu, Sichuan, China
|
|
| 69 |
NCT01502033 |
Completed
Has Results |
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens |
- Major Depressive Disorder
|
- Device: Transcranial Magnetic Stimulation
|
Interventional
|
Not Applicable |
- Paul E. Croarkin
- Mayo Clinic
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Children's Depression Rating Scale-Revised (CDRS-R) Post Treatment 30 or Last Treatment (in Cases of Early Withdrawal)
- Clinical Global Impression - Severity (CGI-S) Post Treatment 30 or Last Treatment (in Cases of Early Withdrawal)
- The Clinical Global Impression - Improvement (CGI-I)
|
10 |
All |
13 Years to 18 Years (Child, Adult) |
NCT01502033 |
11-004500 |
|
December 2011 |
May 2013 |
December 2013 |
December 30, 2011 |
April 22, 2016 |
February 17, 2016 |
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
|
| 70 |
NCT00427128 |
Completed |
Prozac Treatment of Major Depression: Discontinuation Study |
|
- Drug: fluoxetine
- Drug: placebo
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MDD section of Mood Disorders Module of Structured Clinical Interview for DSM-IV (SCID)
- Ham-D
- CGI
|
627 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00427128 |
4099R
RO1 MH56058 |
|
November 1995 |
|
March 2003 |
January 26, 2007 |
December 15, 2011 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - New York State Psychiatric Institute
New York, New York, United States
|
|
| 71 |
NCT01874951 |
Completed
Has Results |
Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence |
- Major Depressive Disorder
- Depression, Unipolar
- Recurrence
- Relapse
|
- Drug: Naltrexone
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- Boston Clinical Trials (BCT)
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in HAM-D-17 Total Score
- Change in HAM-D28 Total Score
- Change in MADRS-10 Total Score
- (and 5 more...)
|
12 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01874951 |
2013P000371 |
|
June 2013 |
June 2015 |
June 2015 |
June 11, 2013 |
February 24, 2017 |
February 24, 2017 |
- Massachusetts General Hospital; Depression Research and Clinical Program
Boston, Massachusetts, United States
|
|
| 72 |
NCT00181896 |
Terminated |
Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder |
- Depression
- Bipolar Disorder
|
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- reduction in depression symptoms assessed by
- Children's Depression Rating Scale
- Hamilton Depression Rating scale (HAM-D)
|
1 |
All |
6 Years to 17 Years (Child) |
NCT00181896 |
2004-P-001727 |
|
January 2005 |
February 2007 |
|
September 16, 2005 |
July 15, 2011 |
|
- Massachusetts General Hospital
Cambridge, Massachusetts, United States
|
|
| 73 |
NCT01582945 |
Completed
Has Results |
Ketamine Infusion for Treatment-resistant Major Depressive Disorder |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response to Ketamine as Measured by Hamilton Depression Rating Scale -28 Items (HAMD28)
|
14 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01582945 |
2010-P-002800 |
|
April 2012 |
September 2014 |
December 2014 |
April 23, 2012 |
April 20, 2017 |
April 20, 2017 |
- Depression Clinical and Research Program - MGH
Boston, Massachusetts, United States
|
|
| 74 |
NCT03414619 |
Recruiting |
The Role of Cognitive Control in the Transdiagnostic Conceptualization of "Intrusive Thoughts" |
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Major Depressive Disorder
|
- Behavioral: Cognitive Control Tasks and Script Driven Imagery
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Health Resources in Action (HRiA)
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Commission Errors on the Go/No Go Task
- Response time on the Stroop Color Word Test
- Perseverative Errors on the Wisconsin Card Sort Test
- (and 3 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03414619 |
2017P002114 |
|
May 18, 2018 |
September 30, 2019 |
September 30, 2019 |
January 30, 2018 |
September 18, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 75 |
NCT00644358 |
Completed
Has Results |
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
- Change Form Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score
- Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score
- Clinical Global Impression - Improvement (CGI-I) Score
|
616 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00644358 |
CLDA-07-DP-04 |
|
December 31, 2007 |
May 31, 2009 |
May 31, 2009 |
March 26, 2008 |
September 25, 2017 |
September 25, 2017 |
- Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States - Affiliated Research Institute
San Diego, California, United States - Collaborative Neuroscience Network, Inc
Torrance, California, United States - (and 35 more...)
|
|
| 76 |
NCT00556140 |
Completed
Has Results |
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression |
|
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
- Bristol-Myers Squibb
- Massachusetts General Hospital
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Depression and Psychosis Response Rate
- Depression and Psychosis Remission Rate
|
16 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00556140 |
2003-P-000990 |
Abilify |
June 2003 |
January 2008 |
January 2008 |
November 9, 2007 |
August 20, 2012 |
August 20, 2012 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 77 |
NCT00183677 |
Completed
Has Results |
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram |
|
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Responder and Remission Status (%), Based on the Depression Rating Scale Score
|
97 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00183677 |
K23MH067111 |
|
July 2003 |
June 2009 |
June 2009 |
September 16, 2005 |
January 4, 2017 |
January 4, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 78 |
NCT01022632 |
Completed |
Effect of Curcumin as Nutraceutical in Patients of Depression |
- Major Depressive Disorder
|
- Dietary Supplement: Curcumin
- Drug: Fluoxetine
- Dietary Supplement: Curcumin and Fluoxetine
|
Interventional
|
Not Applicable |
- Government Medical College, Bhavnagar
- Health and Family Welfare Department, Government of Gujarat, India
- Arjuna Natural Extracts Ltd.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate according to HAM-D17 scale
- Mean change in HAM-D17 score
- Clinical global impression assessment
- (and 2 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01022632 |
Pharmacol no.01 /2008 Research |
|
March 2009 |
January 2010 |
January 2010 |
December 1, 2009 |
January 28, 2010 |
|
- Sir Takthasinhji General Hospital
Bhavnagar, Gujarat, India
|
|
| 79 |
NCT01447576 |
Completed
Has Results |
Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
|
Interventional
|
Phase 2 |
- Otsuka Pharmaceutical Development & Commercialization, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Participants With Adverse Events (AEs).
- Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Scale Score.
- Mean Clinical Global Impression - Improvement (CGI-I) Scale Score.
|
1036 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01447576 |
331-08-212 |
|
September 2009 |
December 2012 |
December 2012 |
October 6, 2011 |
November 6, 2015 |
November 6, 2015 |
- Pacific Clinical Research Medical Group
Arcadia, California, United States - Artemis Institute for Clinical Research
San Diego, California, United States - California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California, United States - (and 29 more...)
|
|
| 80 |
NCT00733980 |
Completed
Has Results |
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: GSK561679
- Other: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Randomization to the End of Treatment Phase (Week 6) in the Bech Melancholia Subscale (Bech) (Items 1, 2, 7, 8, 10 and 13) From the Hamilton Rating Scale for Depression (HamD17).
- Change From Randomization to Weeks 1, 2, and 4 in the Bech Melancholia Scale Score.
- Change From Randomization to Weeks 1, 2, 4, and 6 in the Hamilton Anxiety Scale (HAM A)
- (and 16 more...)
|
150 |
Female |
18 Years to 64 Years (Adult) |
NCT00733980 |
106139 |
|
October 2, 2008 |
June 18, 2010 |
June 18, 2010 |
August 13, 2008 |
November 17, 2017 |
November 17, 2017 |
- GSK Investigational Site
Cerritos, California, United States - GSK Investigational Site
San Diego, California, United States - GSK Investigational Site
Torrance, California, United States - (and 15 more...)
|
|
| 81 |
NCT00812227 |
Completed |
Neural Correlates of Psychodynamic Psychotherapy for Depression |
- Major Depressive Disorder
|
- Behavioral: Psychodynamic Psychotherapy
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Hope for Depression Research Foundation
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Correlation between changes in HAMD-17 and changes in QEEG measurements (theta cordance) from treatment initiation to two weeks after starting treatment
- PET: Treatment-related change in FDG metabolism within regions-of-interest identified at baseline as related to depression severity.
|
35 |
All |
18 Years to 60 Years (Adult) |
NCT00812227 |
2008-P-001181 |
|
August 2008 |
February 2013 |
February 2013 |
December 22, 2008 |
May 13, 2013 |
|
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
|
| 82 |
NCT01701141 |
Completed |
Depression and Dopamine Transporter Function Study Using C-11 Altropane |
- Major Depressive Disorder
- Anhedonia
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- 11C-Altropane Binding
- Behavioral Performance in Probabilistic Reward Task
- Brain Activity during Instrumental Learning Task
- (and 4 more...)
|
150 |
All |
18 Years to 45 Years (Adult) |
NCT01701141 |
2009-P-001360 |
|
January 2012 |
July 2014 |
July 2014 |
October 4, 2012 |
May 21, 2018 |
|
- McLean Hospital
Belmont, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 83 |
NCT00220636 |
Completed
Has Results |
Abilify as an Adjunctive Treatment for Refractory Depression |
- Depressive Disorder, Major
|
|
Interventional
|
Phase 4 |
- St. Luke's-Roosevelt Hospital Center
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HDRS)
- Clinical Global Impressions Improvement Scale (CGI)
- Change in Global Assessment of Functioning Scale (GAFS)
- Change in Beck Depression Inventory (BDI) Score
|
15 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00220636 |
SLR-04-028 |
|
March 2005 |
March 2007 |
January 2008 |
September 22, 2005 |
May 26, 2016 |
February 20, 2015 |
- Depression Evaluation Service, NY State Psychiatric Institute
New York, New York, United States
|
|
| 84 |
NCT01478113 |
Terminated
Has Results |
Stimulant Enhancement of Well-Being Therapy for Depression |
- Major Depressive Disorder
|
- Drug: Amphetamine/dextroamphetamine
- Drug: Placebo
- Behavioral: Well-being therapy
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Harvard Medical School
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Hamilton-Depression Rating Scale(SIGH-D)-17 Items
- Change in Hamilton-Depression Rating Scale(SIGH-D)-31 Item
- Change in Psychological Well-being Scale (PWB)
- (and 4 more...)
|
5 |
All |
18 Years to 60 Years (Adult) |
NCT01478113 |
2011P002148
2011D002171 |
|
February 2012 |
July 2014 |
July 2015 |
November 23, 2011 |
April 26, 2017 |
April 26, 2017 |
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
|
| 85 |
NCT00562367 |
Completed |
Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones |
- Major Depressive Disorder
|
- Drug: Cytomel (liothyronine)
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- change in depression (as measured by Ham-D-17) over the 4 weeks study
- change in bioenergetic metabolism (e.g., NTP and PCr) as measured by phosphorus magnetic resonance spectroscopy (P31-MRS)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00562367 |
2001-P-000836 |
|
October 2001 |
|
September 2004 |
November 22, 2007 |
November 22, 2007 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 86 |
NCT00998959 |
Completed |
Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients |
- Major Depressive Disorder
|
- Behavioral: Mindfulness Based Stress Reduction and Psychoeducation
- Behavioral: Psychoeducation
|
Interventional
|
Not Applicable |
- Trina E. Chang, MD
- Dupont-Warren
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility (rate of enrollment, attrition)
- Perceived stress
|
40 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00998959 |
2008p001576 |
|
August 2008 |
January 2012 |
January 2012 |
October 21, 2009 |
April 30, 2012 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 87 |
NCT01726387 |
Completed |
Self-Management for Anxiety, Depression and Somatoform Disorders |
- Anxiety Depression (Mild or Not Persistent)
- Major Depressive Disorder, Single Episode, Unspecified
- Neurotic, Stress-related and Somatoform Disorders
|
- Behavioral: Psychosocial Counseling
- Behavioral: Usual Care
|
Interventional
|
Not Applicable |
- Universitätsklinikum Hamburg-Eppendorf
- German Federal Ministry of Education and Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- General Self-Efficacy Scale (GSE)
- Change in Symptom Score Patient's Health Questionnaire (German Version)
- Health Related Quality of Life
|
364 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01726387 |
SMADS |
SMADS |
March 2013 |
September 2015 |
September 2015 |
November 14, 2012 |
February 6, 2018 |
|
- Primary Care Practices
Hamburg, Germany
|
|
| 88 |
NCT03287037 |
Recruiting |
The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression |
- Depressive Disorder, Major
- Depression, Bipolar
- Electricity; Effects
|
|
Interventional
|
Not Applicable |
- Tri-Service General Hospital
- Tri-Service General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes from baseline score of Hamilton Depression Rating Scale (HAM-D) at the timepoint immediately after tDCS, at one week and one month after tDCS
- Changes from baseline score of Young Mania Rating Scale (YMRS) at the timepoint immediately after tDCS, at one week and one month after tDCS
- Changes from baseline score of Hamilton Anxiety Rating Scale (HAM-A) at the timepoint immediately after tDCS, at one week and one month after tDCS
- (and 2 more...)
|
120 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03287037 |
2-103-03-002-1 |
|
October 2016 |
December 2018 |
June 2022 |
September 19, 2017 |
September 19, 2017 |
|
- Tri-service general hospital
Taipei, Taiwan
|
|
| 89 |
NCT03666390 |
Recruiting |
Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide |
- Major Depressive Disorder
|
- Drug: Ketamine
- Drug: Midazolam
|
Interventional
|
Not Applicable |
- Taipei Veterans General Hospital, Taiwan
- Taipei Veterans General Hospital, Taiwan
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction rate of suicide symptom
- Reduction rate of depression symptom
|
48 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03666390 |
107-2314-B-075-063-MY3 |
|
September 10, 2018 |
December 31, 2021 |
December 31, 2021 |
September 11, 2018 |
September 19, 2018 |
|
- Taipei Veterans General Hospital
Taipei, Taiwan
|
|
| 90 |
NCT02431806 |
Recruiting |
Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Placebo
- Drug: Levomilnacipran ER
- Drug: Fluoxetine
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Children's Depression Rating Scale-Revised (CDRS-R) total score
- Change in Clinical Global Impression-Severity (CGI-S) scale
|
660 |
All |
12 Years to 17 Years (Child) |
NCT02431806 |
LVM-MD-11 |
|
June 23, 2015 |
December 21, 2018 |
December 21, 2018 |
May 1, 2015 |
October 12, 2018 |
|
- Harmonex, Inc
Dothan, Alabama, United States - Noesis Pharma
Phoenix, Arizona, United States - University of Arizona Department of Psychiatry
Tucson, Arizona, United States - (and 88 more...)
|
|
| 91 |
NCT01804296 |
Enrolling by invitation |
rTMS for Depressed Teens: A Sham-Controlled Trial, Part 2 |
- Major Depressive Disorder
|
- Device: Repetitive transcranial magnetic stimulation (rTMS)
|
Interventional
|
Not Applicable |
- Paul E. Croarkin
- Mayo Clinic
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean change from Baseline in Children's Depression Rating Scale-Revised (CDRS-R) post Treatment 30 or Last Treatment (in the case of early withdrawal)
- Mean change from Baseline in Clinical Global Impression - Severity (CGI-S) post Treatment 30 or Last Treatment (in the case of early withdrawal)
- Mean Clinical Global Impression - Improvement (CGI-I) Score post Treatment 30 or Last Treatment (in the case of early withdrawal)
|
50 |
All |
12 Years to 21 Years (Child, Adult) |
NCT01804296 |
12-003248 Part 2 |
|
March 2013 |
December 2018 |
December 2018 |
March 5, 2013 |
October 19, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States - Medical University of South Carolina
Charleston, South Carolina, United States
|
|
| 92 |
NCT01804270 |
Active, not recruiting |
rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1 |
- Major Depressive Disorder
|
- Device: Repetitive transcranial magnetic stimulation (rTMS)
|
Interventional
|
Not Applicable |
- Paul E. Croarkin
- Mayo Clinic
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from Baseline in Children's Depression Rating Scale-Revised (CDRS-R) post Treatment 30 or Last Treatment (in the case of early withdrawal)
- Mean change from Baseline in Clinical Global Impression - Severity (CGI-S) post Treatment 30 or Last Treatment (in the case of early withdrawal)
- Mean Clinical Global Impression - Improvement (CGI-I) Score post Treatment 30 or Last Treatment (in the case of early withdrawal)
|
50 |
All |
12 Years to 21 Years (Child, Adult) |
NCT01804270 |
12-003248 Part 1 |
|
April 2013 |
December 2018 |
December 2018 |
March 5, 2013 |
February 26, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States - Medical University of South Carolina
Charleston, South Carolina, United States
|
|
| 93 |
NCT00715559 |
Terminated
Has Results |
Cysteamine Therapy for Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: cysteamine bitartrate
|
Interventional
|
Not Applicable |
- Icahn School of Medicine at Mount Sinai
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- Clinical Global Impression Scales for Severity (CGI-S) and Improvement (CGI-I)
- Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16)
- Systematic Assessment for Treatment Emergent Effects (SAFTEE)
|
3 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00715559 |
GCO # 07-0478 |
|
July 2008 |
May 2009 |
May 2009 |
July 15, 2008 |
April 7, 2017 |
June 16, 2011 |
- Mount Sinai School of Medicine
New York, New York, United States
|
|
| 94 |
NCT01893749 |
Completed |
Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health |
- Major Depression
- Depressive Episodes
|
|
Interventional
|
Not Applicable |
- Benjamin Van Voorhees, MD, MPH
- Wellesley College
- Northwestern University
- (and 7 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- The Center for Epidemiological Studies of Depression(CES-D)Scale
- Kiddie Schedule of Affective Disorders Scale(KSADS)
- Vulnerability Factors
|
1142 |
All |
13 Years to 18 Years (Child, Adult) |
NCT01893749 |
1R01MH090035-01A1 |
CATCH-IT |
February 2012 |
July 2016 |
July 2016 |
July 9, 2013 |
November 2, 2016 |
|
- ACCESS Healthcare Systems
Chicago, Illinois, United States - University of Illinois
Chicago, Illinois, United States - Northshore Healthcare Systems
Evanston, Illinois, United States - (and 4 more...)
|
|
| 95 |
NCT01210651 |
Completed
Has Results |
Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial |
|
- Behavioral: Hatha Yoga Practice Group
- Behavioral: Attention Control Education Group
|
Interventional
|
Not Applicable |
- University of California, San Francisco
- Mental Insight Foundation
- Pritzker Family Foundation
- Mount Zion Health Fund
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Intent-to-Treat Analysis of Adjusted Mean Beck Depression Inventory-II Scores Over Intervention Period
- Total Change Scores on Beck Depression Inventory-II Among Study Completers
- Number of Study Completers With Remitted Depression, Per Completers Analysis of BDI Scores at 8 Weeks
- (and 2 more...)
|
38 |
All |
14 Years and older (Child, Adult, Older Adult) |
NCT01210651 |
H49362-35940-01 |
|
May 2010 |
January 2011 |
January 2011 |
September 28, 2010 |
January 11, 2017 |
January 11, 2017 |
- University of California San Francisco
San Francisco, California, United States
|
|
| 96 |
NCT00179257 |
Completed |
The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram |
- Major Depressive Disorder
|
- Drug: sertraline (Zoloft)
|
Interventional
|
Phase 3 |
- Vanderbilt University
- Pfizer
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q)
- Hamilton Rating Scale for Depression (21-item) total score
- Clinical Global Impressions - Improvement Scale
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT00179257 |
Lexapro Failure Study |
|
June 2004 |
|
March 2005 |
September 15, 2005 |
June 2, 2015 |
|
|
|
| 97 |
NCT02078817 |
Completed |
Ketamine in Adolescents With Treatment-Resistant Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 2 |
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Global Impression
- Children's Depression Rating Scale-Revised
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- (and 7 more...)
|
14 |
All |
12 Years to 18 Years (Child, Adult) |
NCT02078817 |
22225 |
|
September 2014 |
March 2018 |
March 2018 |
March 5, 2014 |
March 6, 2018 |
|
- University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 98 |
NCT00404755 |
Completed
Has Results |
Dichotic Listening as a Predictor of Medication Response in Depression |
- Major Depressive Disorder
- Dysthymia
|
- Drug: escitalopram
- Drug: bupropion
- Drug: imipramine
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Scale (HAM-D)
- Clinical Global Impression Scale (CGI)
|
17 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00404755 |
#5294R
IRB 5294R |
|
July 2006 |
August 2011 |
August 2011 |
November 29, 2006 |
April 30, 2018 |
March 15, 2018 |
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 99 |
NCT01123707 |
Terminated |
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder (MDD)
|
- Drug: Aripiprazole/Escitalopram combination therapy
|
Interventional
|
Phase 3 |
- Otsuka Pharmaceutical Development & Commercialization, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety - based on the frequency and severity of AEs & SAEs
- Efficacy
|
170 |
All |
18 Years to 66 Years (Adult, Older Adult) |
NCT01123707 |
31-08-257 |
ACES 257 |
November 2010 |
July 2011 |
December 2011 |
May 14, 2010 |
August 31, 2012 |
|
- Birmingham, Alabama, United States
- Tucson, Arizona, United States
- Little Rock, Arkansas, United States
- (and 59 more...)
|
|
| 100 |
NCT02294305 |
Unknown † |
Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder |
- Social Anxiety Disorder
- Major Depressive Disorder
|
- Drug: Vortioxetine
- Drug: Placebo
|
Interventional
|
Phase 4 |
- The Medical Research Network
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical Global Impression of Improvement (CGI-I) Responder Rate
- Change in total Montgomery Asberg Depression Rating Scale (MADRS) score
- Change in total Liebowitz Social Anxiety Scale (LSAS) score
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02294305 |
TAK-S001560 |
|
December 2014 |
November 2016 |
November 2016 |
November 19, 2014 |
August 24, 2016 |
|
- The Medical Research Network, LLC
New York, New York, United States
|
|
Create an RSS feed from your search for:
Download the search results for: